Fibroblast growth factor receptors (FGFR) Inhibition for Epithelial Solid Tumours: a phase Ib trial of AZD4547 in combination with gemcitabine and cisplatin

Trial Profile

Fibroblast growth factor receptors (FGFR) Inhibition for Epithelial Solid Tumours: a phase Ib trial of AZD4547 in combination with gemcitabine and cisplatin

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs AZD 4547 (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Acronyms FIESTA
  • Most Recent Events

    • 02 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 01 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Interim results (n=19) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top